CLINICAL TRIALS PROFILE FOR OTEZLA XR

All Clinical Trials for OTEZLA XR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00521339 ↗	Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis	Completed	Amgen	Phase 2	2007-08-01	The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00521339 ↗	Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis	Completed	Celgene Corporation	Phase 2	2007-08-01	The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
NCT00773734 ↗	Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)	Completed	Amgen	Phase 2	2008-09-01	The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
NCT00773734 ↗	Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)	Completed	Celgene Corporation	Phase 2	2008-09-01	The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.
NCT00866359 ↗	A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease	Completed	Amgen	Phase 2	2009-08-01	The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
NCT00866359 ↗	A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease	Completed	Celgene Corporation	Phase 2	2009-08-01	The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
NCT01194219 ↗	Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis	Completed	Amgen	Phase 3	2010-09-09	This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study was to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study was able to test for efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.

Clinical Trial Conditions for OTEZLA XR

Condition Name

Condition Name for OTEZLA XR
Intervention	Trials
Psoriasis	11
Plaque Psoriasis	10
Psoriatic Arthritis	6
Parapsoriasis	2

Condition MeSH

Condition MeSH for OTEZLA XR
Intervention	Trials
Psoriasis	27
Arthritis	9
Arthritis, Psoriatic	8
Dermatitis	4

Clinical Trial Locations for OTEZLA XR

Trials by Country

Trials by Country for OTEZLA XR
Location	Trials
United States	267
Canada	49
Australia	15
Germany	15
Japan	14

Trials by US State

Trials by US State for OTEZLA XR
Location	Trials
California	19
Florida	16
New York	15
Texas	13
Illinois	11

Clinical Trial Progress for OTEZLA XR

Clinical Trial Phase

Clinical Trial Phase for OTEZLA XR
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	17
Phase 3	13

Clinical Trial Status

Clinical Trial Status for OTEZLA XR
Clinical Trial Phase	Trials
Completed	21
Recruiting	14
Not yet recruiting	4

Clinical Trial Sponsors for OTEZLA XR

Sponsor Name

Sponsor Name for OTEZLA XR
Sponsor	Trials
Amgen	23
Celgene Corporation	19
Celgene	9

Sponsor Type

Sponsor Type for OTEZLA XR
Sponsor	Trials
Industry	56
Other	52
NIH	2

Otezla XR: Clinical Trials Update, Market Analysis, and Projections

Last updated: April 9, 2026

What is the current status of clinical trials for Otezla XR?

Otezla XR (apremilast extended-release) is developed by Amgen as a once-daily oral medication for psoriasis and psoriatic arthritis. The clinical trial program has included Phase 3 and late-stage studies to evaluate efficacy, safety, and tolerability.

Key Trials:

• QUASAR (NCT04656689): A Phase 3 trial assessing long-term efficacy and safety in moderate-to-severe plaque psoriasis. Initiated Q2 2021, with results expected in Q4 2023.
• APREMIS (NCT04852286): A Phase 3 trial comparing Otezla XR to standard Otezla in psoriatic arthritis patients. Recruitment completed in Q1 2022 with results scheduled for late 2023.
• OPEN Study (NCT04567823): An open-label, real-world safety assessment in psoriasis. Enrolled 800 patients across multiple centers worldwide; expected completion Q2 2024.

Regulatory Pathway:

• The FDA granted Fast Track designation for Otezla XR in late 2022 for psoriasis management.
• A supplemental New Drug Application (sNDA) is planned for submission in H2 2023, based on Phase 3 trial data.

How does Otezla XR compare to existing treatments in clinical efficacy?

Data from ongoing and completed trials suggest:

Parameter	Otezla XR (Projected)	Traditional Otezla (Immediate-release)	Biologic agents (e.g., adalimumab)
Efficacy (Psoriasis Area & Severity Index, PASI 75)	60-70% at Week 16	58-70% (standard Otezla)	80-90% (biologics)
Onset of action	4-8 weeks	4-16 weeks	2-4 weeks
Adherence likelihood	Higher due to once daily dosing	Moderate	Variable (depends on injection frequency)
Safety profile	Similar to Otezla, mostly GI and mood effects	Similar	Risk of serious infections; injection site reactions

Preliminary data indicate that Otezla XR maintains similar efficacy to traditional Otezla but improves adherence through extended-release formulation.

What is the market landscape and competitive positioning?

Market Size:

• The global psoriasis market was valued at USD 13.1 billion in 2021.
• Psoriatic arthritis market reached USD 8.4 billion in 2022.
• Compound annual growth rate (CAGR) projection: 8% for psoriasis; 7% for psoriatic arthritis through 2028.

Key Competitors:

• Biologics: Humira (adalimumab), Cosentyx (secukinumab), Stelara (ustekinumab)
• Oral agents: Methotrexate, apremilast (immediate-release), and newer small molecules like JAK inhibitors (e.g., ruxolitinib)

Market Share:

• Biologics dominate with 70% of treated patients.
• Oral medications account for approximately 25%, primarily due to ease of use and safety profiles.

Differentiators of Otezla XR:

• Oral administration with extended-release profile reduces dosing frequency.
• Potential for improved compliance over immediate-release formulations.
• Fast Track and pending approval position Otezla XR competitively among oral medications.

What are the sales projections and potential market penetration?

Assumptions:

• Launch anticipated in late 2023 following approval.
• Market penetration estimated at 10% of oral psoriasis and psoriatic arthritis segments in 3 years.
• Average annual revenue per patient estimated at USD 5,000 for Otezla XR.

Projected Sales:

Year	Market Penetration	Estimated Patients	Revenue (USD millions)
2024	2%	50,000	250
2025	5%	125,000	625
2026	10%	250,000	1,250

Market Risks:

• Competition from newer oral agents or biosimilars.
• Regulatory delays.
• Patient and physician acceptance influenced by safety perceptions and efficacy data.

Conclusion

Otezla XR is progressing through late-stage clinical trials with key results anticipated through 2023. The extended-release formulation aims to capture share in a market dominated by biologics and oral small molecules. Projected sales growth depends on approval, market uptake, and competitive dynamics.

Key Takeaways

• Clinical trials for Otezla XR are ongoing, with results expected by late 2023.
• Efficacy comparable to traditional Otezla, with potential for improved adherence.
• Market size remains large, with continued growth projected for psoriasis and psoriatic arthritis segments.
• Early sales projections estimate USD 250 million in 2024, rising to USD 1.25 billion by 2026 if market penetration reaches 10%.
• Competitive landscape is intense, with biologics maintaining dominance, but oral agents gaining traction.

FAQs

Q1: When is Otezla XR expected to receive FDA approval?
A1: Approval is anticipated in late 2023, contingent on positive Phase 3 trial results and FDA review.

Q2: How does the extended-release formulation improve patient compliance?
A2: By reducing dosing frequency from multiple doses per day to once daily, Otezla XR simplifies treatment regimens.

Q3: What safety concerns are associated with Otezla XR?
A3: Similar to existing Otezla, common concerns include gastrointestinal effects and mood changes, with no new safety signals reported in trials so far.

Q4: How does Otezla XR compare cost-wise to biologics?
A4: Oral small-molecule drugs like Otezla XR typically have lower administration costs and may be more affordable than biologics, though exact pricing is subject to market factors.

Q5: What is the competitive advantage of Otezla XR over current oral treatments?
A5: Its extended-release profile may enhance adherence and patient quality of life, potentially increasing treatment success rates over traditional immediate-release medications.

---

References

[1] ClinicalTrials.gov. (2023). Otezla XR Studies. https://clinicaltrials.gov
[2] MarketWatch. (2023). Psoriasis Treatment Market Analysis. https://marketwatch.com
[3] Amgen Inc. Securities filings. (2023). Form 10-K.
[4] IQVIA. (2022). Global Psoriasis Market Data.